These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1168 related items for PubMed ID: 22617188

  • 1. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 2. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
    Komajda M, Böhm M, Borer J, Ford I, Krum H, Tase A, Tavazzi L, Swedberg K.
    Eur J Heart Fail; 2013 Jan 29; 15(1):79-84. PubMed ID: 22892123
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K, SHIFT Investigators.
    Am J Cardiol; 2014 Feb 01; 113(3):497-503. PubMed ID: 24332674
    [Abstract] [Full Text] [Related]

  • 4. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, Maack C, Lainscak M, Swedberg K, Tavazzi L.
    Am J Cardiol; 2015 Dec 15; 116(12):1890-7. PubMed ID: 26508709
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L.
    Eur J Heart Fail; 2010 Jan 15; 12(1):75-81. PubMed ID: 19892778
    [Abstract] [Full Text] [Related]

  • 6. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 7. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 8. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Robertson M, Ford I, SHIFT Investigators.
    Int J Cardiol; 2013 Dec 10; 170(2):182-8. PubMed ID: 24225201
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
    Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, Pittalis M, De Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di Francesco D, Lupo PP.
    J Am Coll Cardiol; 2012 Oct 09; 60(15):1323-9. PubMed ID: 22981555
    [Abstract] [Full Text] [Related]

  • 10. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):886-94. PubMed ID: 20801495
    [Abstract] [Full Text] [Related]

  • 11. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):875-85. PubMed ID: 20801500
    [Abstract] [Full Text] [Related]

  • 12. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Sep 11; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 13. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart; 2011 Dec 11; 97(23):1961-6. PubMed ID: 21917660
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 11; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 15. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Nov 11; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 16. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K.
    Eur Heart J; 2013 Aug 11; 34(29):2263-70. PubMed ID: 23536611
    [Abstract] [Full Text] [Related]

  • 17. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA, Böhm M, Borer JS, Ford I, Komajda M, Swedberg K, Tavazzi L, SHIFT investigators.
    Cardiology; 2015 Aug 11; 131(4):218-24. PubMed ID: 25968495
    [Abstract] [Full Text] [Related]

  • 18. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 19. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L, Fragasso G, Spoladore R, Pinto G, Gemma M, Slavich M, Godino C, Salerno A, Montanaro C, Margonato A.
    J Cardiovasc Med (Hagerstown); 2018 Jul 27; 19(7):351-356. PubMed ID: 29762337
    [Abstract] [Full Text] [Related]

  • 20. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.
    Flannery G, Gehrig-Mills R, Billah B, Krum H.
    Am J Cardiol; 2008 Mar 15; 101(6):865-9. PubMed ID: 18328855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.